The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Non-steroidal anti-inflammatory drugs and bladder cancer prevention
Open accessAbstract
Inclusion of phenacetin among 'proven' human carcinogens by the IARC in 1987, raised concerns about the carcinogenic potential of acetaminophen, its major metabolite. Acetaminophen has been implicated as a possible causal agent in the development of cancer of the renal pelvis. The bladder and renal pelvis, which derive from the same embryological structure, share the same transitional type of epithelium. Past studies have been inconclusive on the possible relationship among these analgesics and bladder cancer but no large, highly detailed study of this association has been conducted. A population-based case-control study conducted in Los Angeles, California, involved 1514 incident bladder cancer cases and an equal number of controls who were matched to the index cases by sex, date of birth (within 5 years) and race. Detailed information on medication use and prior medical conditions was collected through in-person interviews. Regular use of analgesics was not associated with an increased risk of bladder cancer in either men or women. In fact, compared with non- or irregular users, regular analgesic users were at a decreased risk of bladder cancer overall (odds ratio (OR) = 0.81, 95% confidence interval (CI) = 0.68-0.96). However, there were clear differences in both the direction and strength of the associations between the different formulation classes of analgesics and bladder cancer risk. Intake of phenacetin was positively related to bladder cancer risk in a dose-dependent manner while intake of its major metabolite in humans, acetaminophen, was unrelated to risk. Intake of all classes of NSAIDs, except pyrazolon derivatives, were negatively associated with bladder cancer risk, with suggestive evidence that the protective effect varies in strength by subcategories of formulation. Acetic acids seemed to exhibit the strongest protective effect, whereas aspirin/other salicylic acids and oxicam showed the weakest protection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367
Cited by
Thun, M. J., Henley, S. J., & Patrono, C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.252 · Cited by 1,433
Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2
Gupta, R. A., & DuBois, R. N. (2001) · Nature Reviews Cancer · doi:10.1038/35094017 · Cited by 1,066
Tumor microenvironment: The role of the tumor stroma in cancer
Li, H., Fan, X., & Houghton, J. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21159 · Cited by 646
Chronic immune activation and inflammation as the cause of malignancy
O'Byrne, K. J., & Dalgleish, A. G. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1943 · Cited by 543
Aspirin and cancer risk: a quantitative review to 2011
Bosetti, C., Rosato, V., Gallus, S., Cuzick, J., & La Vecchia, C. (2012) · Annals of Oncology · doi:10.1093/annonc/mds113 · Cited by 297
Metadata
- Authors
- Castelao, J. E., Yuan, J.-M., Gago-Dominguez, M., Yu, M. C., & Ross, R. K.
- Venue
- British Journal of Cancer
- Published
- 2000-04
- Volume
- 82
- Issue
- 7
- Pages
- 1364-1369
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1590255381
- Cited by
- 214
- References
- 1
- FWCI
- 10.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Non-steroidal anti-inflammatory drugs and bladder cancer prevention. https://app.cochat.ai/papers/10.1054/bjoc.1999.1106
- The paper
- Castelao, J. E., Yuan, J.-M., Gago-Dominguez, M., Yu, M. C., & Ross, R. K. (2000). Non-steroidal anti-inflammatory drugs and bladder cancer prevention. British Journal of Cancer. https://doi.org/10.1054/bjoc.1999.1106
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.